The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future.
about
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquineEstablishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missingKetamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSnCYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysisNew cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine.Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics.The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes.Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques.Engineering of a functional human NADH-dependent cytochrome P450 systemInteractions of herbs with cytochrome P450.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Human carbonyl reduction pathways and a strategy for their study in vitro.Cytochrome P450 humanised mice.In silico and in vitro pharmacogenetic analysis in miceHeterologous expression of human cytochrome P450 2E1 in HepG2 cell lineCloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.Steroid biotransformations in biphasic systems with Yarrowia lipolytica expressing human liver cytochrome P450 genes.Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies.Application of the Amplex red/horseradish peroxidase assay to measure hydrogen peroxide generation by recombinant microsomal enzymes.In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.In vitro approaches to studying the metabolism of new psychoactive compounds.An overview of on-line systems using drug metabolizing enzymes integrated into capillary electrophoresis.Reaction phenotyping to assess victim drug-drug interaction risks.Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog.Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4.A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS.In silico pharmacogenetics of warfarin metabolism.Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies.In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies.Characterization of mixtures of recombinant human cytochrome p450s as a screening model for metabolic stability in drug discovery.Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study.Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives
P2860
Q21034109-6AB3A18F-F791-4C9E-817D-D649671D2683Q28207445-9627501D-EA4E-40D5-BD3F-28EFDFC503B9Q28292983-9A866067-37E2-4000-B855-787F4F934FA7Q28568816-0D20C9C1-EE3D-4A62-8A19-FAF3790B5A8BQ34167745-D074076D-9B55-4DFF-A000-5DC0154D4C38Q34224925-C2F6D668-4D29-4B0E-8F9E-21CC2C76F07DQ34269371-495CD136-1634-4673-A0A1-809821D770F6Q34343253-B80F5026-A301-4367-B700-C7B5D993908DQ34377572-AA480C4A-1F39-4E77-A8F5-83819CF5CE9AQ34430456-A2AC4A20-2851-4F6B-89DE-D2992F0D5B71Q34434069-109340A2-FC3A-4CB5-B319-E647B536B0F9Q34451894-11ABC613-4401-4951-A844-2FEA07A4A9CBQ34583746-BD5F623A-B417-4CE8-B198-1F831504E713Q35085032-C083A9ED-B75B-49C3-911E-FABE765FBE90Q35129048-BD259933-63DD-461E-8310-E9EC77C29838Q35828036-5A684364-086B-4A01-87A2-239C531A8BE0Q35978586-316CEB0E-969D-44D6-ADAE-6AC2530E57F0Q36140849-2AE9BE11-032F-46AD-A435-B2DCCBD3E97CQ36180508-49FBE184-7BE1-4EA6-894C-7401E010BDEAQ36316100-399BE176-D2E8-43CD-A7EF-279E00D38758Q36531595-6A52A264-B998-4D15-8E1A-2BBDA7C1A489Q36546250-8C90F2E4-2290-4192-A893-FDDE457715DCQ36814285-495AB484-7FA3-4A2F-97BF-FBF469C55C40Q36985051-542CFAD4-3C53-4081-8B0A-A1E80C9B7ACDQ37121662-E5B9ED20-0902-4125-98DD-BA6303B9E6BCQ37889234-697AF15A-8098-4C59-9954-6ECCE17A06E6Q38115265-F9128FE3-EC19-42A0-8B89-7B7DCE951C2DQ38640403-BCCB5663-2B97-49D7-9A0F-2C6FD2CED293Q38807784-C7894C5C-0491-4E54-87E2-8A3B6EE8E4A6Q39732707-01AAD067-80B3-460C-9386-40574182EC3DQ40515289-F15022D2-291F-481E-9E42-EED0D7D7AA18Q40568343-FFD671EA-2437-402D-B651-DE950A85A531Q41894196-FE0C1345-AD45-4184-A47A-D531370D63FAQ43730577-DF4D9C4B-AA68-4692-80BE-ADB8B283D86EQ43754354-7E5C9526-254E-4B11-821A-E304D61B0405Q43932208-62A6676A-63BC-45FF-85E8-F59DBEF9445FQ44191382-72F8247F-0750-4A82-A3C8-7B903F9443DBQ54329484-1DF7B1BF-2EC5-45A6-8EEA-ADEC5305D5B3Q58804131-C3209ABC-55E4-41DF-87B0-87207ACD901F
P2860
The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The use of heterologously expr ...... and prospects for the future.
@ast
The use of heterologously expr ...... and prospects for the future.
@en
type
label
The use of heterologously expr ...... and prospects for the future.
@ast
The use of heterologously expr ...... and prospects for the future.
@en
prefLabel
The use of heterologously expr ...... and prospects for the future.
@ast
The use of heterologously expr ...... and prospects for the future.
@en
P1476
The use of heterologously expr ...... and prospects for the future.
@en
P2093
P304
P356
10.1016/S0163-7258(99)00028-5
P577
1999-11-01T00:00:00Z